ABILITY Neurotech receives approval to start clinical trial

▤ Summary

ABILITY Neurotech has received approval in the Netherlands to begin its first chronic implantation study of a fully implantable brain-computer interface. The company’s platform is designed to restore communication and autonomy for patients with severe neurological conditions such as ALS, spinal cord injury, and stroke. The study at UMC Utrecht will test the system as a home-use communication tool and marks the transition from intra-operative testing to long-term human evaluation. The article highlights the company’s optical link, neural data capture capabilities, and broader plan to support AI-driven BCI applications.

▦ Linked Companies